Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment

Atherosclerosis

Volumn 196, Issue 1, 2008, Pages 289-297

  Papathanasiou, Athanasios I ^a   Lourida, Evangelia S ^b   Tsironis, Loukas D ^b   Goudevenos, John A ^a   Tselepis, Alexandros D ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atherosclerosis; Atorvastain; Autoantibodies; Lipoprotein associated phospholipase A2; Lipoproteins; Oxidation; PAF acetylhydrolase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; AUTOANTIBODY; IMMUNOGLOBULIN G; OXIDIZED LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SMOKING HABIT; ST SEGMENT ELEVATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACUTE CORONARY SYNDROME; AGED; AUTOANTIBODIES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULIN G; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRROLES;

EID: 38049026748     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.10.033     Document Type: Article

References (28)

1. Navab M., Ananthramaiah G.M., Reddy S.T., et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45 (2004) 993-1007
2. Itabe H. Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol Pharm Bull 26 (2003) 1-9
3. Esterbauer H., Gebicki J., Puhl H., and Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13 (1992) 341-390
4. Wu R., Huang Y.H., Elinder L.S., and Frostegard J. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler Thromb Vasc Biol 18 (1998) 626-630
5. Palinski W., and Witztum J.L. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 247 (2000) 371-380
6. 2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 3 (2002) 57-68
7. Lourida E.S., Papathanasiou A., Goudevenos J., and Tselepis A.D. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease. Prostag Leukot Essent Fatty Acids 75 (2006) 117-126
8. Edelstein C., Pfaffinger D., Hinman J., et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 278 (2003) 52841-52847
9. Tsouli S.G., Kiortsis D.N., Lourida E.S., et al. Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia. J Lipid Res 47 (2006) 2208-2214
10. Ehara S., Ueda M., Naruko T., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103 (2001) 1955-1960
11. Holvoet P., Collen D., and Van-de-Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 281 (1999) 1718-1721
12. Tsimikas S., Bergmark C., Beyer R., et al. Temporal increases in plasma markers of oxidized low-density liporpotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 41 (2003) 360-370
13. Liapikos Th., Antonopoulou S., Karabina S.-A., Tsoukatos D.C., Demopoulos C.A., and Tselepis A.D. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochem Biophys Acta 1212 (1994) 353-360
14. Dentan C., Lesnik P., Chapman M.J., and Ninio E. PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation. Arterioscler Thromb 14 (1994) 353-360
15. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353 (2005) 46-57
16. Tsimikas S., Lau H., Han S., et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a). Circulation 109 (2004) 3164-3170
17. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 (2002) 1366-1374
18. Dentan C., Tselepis A.D., Chapman M., and Ninio E. Pefabloc 4-[2-Aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim Biophys Acta 1299 (1996) 353-357
19. Karabina S.-A., Liapikos Th, Grekas G., Goudevenos J., and Tselepis A.D. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein. Biochim Biophys Acta 1213 (1994) 34-38
20. Tsimihodimos V., Karabina S.-A., Tambaki A., et al. Altered distribution of PAF-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 43 (2002) 256-263
21. Inoue T., Uchida T., Kamishirado H., Takayanagi K., and Morooka S. Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. J Am Coll Cardiol 37 (2001) 1871-1876
22. Tsimikas S., and Witztum J.L. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 103 (2001) 1930-1932
23. Inoue T., Uchida T., Kamishirado H., Takayanagi K., Hayashi T., and Morroka S. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol 37 (2001) 775-779
24. Tsimikas S., Witztum J.L., Miller E.R., et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110 (2004) 1406-1412
25. van Tits L.J.H., van Himebergen T.M., Lemmers H.L.M., de Graaf J., and Stalenhoef A.F.H. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 185 (2006) 1307-1312
26. Aviram M., Rosenblat M., and Bisgaier C.L. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138 (1998) 271-280
27. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22 (2001) 554-572
28. Pitsavos C., Panagiotakos D.B., Antonoulas A., et al. Epidemiology of acute coronary syndromes in a Mediterranean country; aims, design and baseline characteristics of the Greek study of acute coronary syndromes (GREECS). BMC Public Health 5 (2005) 23